These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 26554348)

  • 1. Progress Toward the Validation of Alternative Tests.
    Balls M; Fentem JH
    Altern Lab Anim; 1997; 25(1):33-43. PubMed ID: 26554348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop.
    Gennari A; Ban M; Braun A; Casati S; Corsini E; Dastych J; Descotes J; Hartung T; Hooghe-Peters R; House R; Pallardy M; Pieters R; Reid L; Tryphonas H; Tschirhart E; Tuschl H; Vandebriel R; Gribaldo L
    J Immunotoxicol; 2005 Apr; 2(2):61-83. PubMed ID: 18958661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eye Irritation Testing: The Way Forward. The Report and Recommendations of ECVAM Workshop 34.
    Balls M; Berg N; Bruner LH; Curren RD; de Silva O; Earl LK; Esdaile DJ; Fentem JH; Liebsch M; Ohno Y; Prinsen MK; Spielmann H; Worth AP
    Altern Lab Anim; 1999; 27(1):53-77. PubMed ID: 25423402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ECVAM's in-house prevalidation/validation studies in the areas of haematotoxicity, reproductive toxicity, metabolism-mediated toxicity and epithelial barrier function.
    Prieto P
    Sci Total Environ; 2000 Mar; 247(2-3):349-54. PubMed ID: 10803561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future activities: ECVAM and the quality control of biologicals.
    Cussler K; Halder M; Hendriksen C
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():225-6. PubMed ID: 12513681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of ECVAM: a personal perspective.
    Balls M
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():239-41. PubMed ID: 12513683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ECVAM prevalidation study on in vitro cell transformation assays: general outline and conclusions of the study.
    Corvi R; Aardema MJ; Gribaldo L; Hayashi M; Hoffmann S; Schechtman L; Vanparys P
    Mutat Res; 2012 Apr; 744(1):12-9. PubMed ID: 22138617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ECVAM's contributions to the implementation of the Three Rs in the production and quality control of biologicals.
    Halder M; Hendriksen C; Cussler K; Balls M
    Altern Lab Anim; 2002; 30(1):93-108. PubMed ID: 11827574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ECVAM's collaborations with academia.
    Clothier R
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():175-83. PubMed ID: 12513670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ECVAM's approach to intellectual property rights in the validation of alternative methods.
    Linge JP; Hartung T
    Altern Lab Anim; 2007 Aug; 35(4):441-6. PubMed ID: 17850189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ECVAM's activities in promoting the Three Rs in the quality control of biologicals.
    Halder M; Balls M; Hendriksen C; Cussler K
    Altern Lab Anim; 2004 Jun; 32 Suppl 1A():93-8. PubMed ID: 23577439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ECVAM's activities on biologicals.
    Halder M; Balls M; Hendriksen C; Cussler K
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():125-8. PubMed ID: 12513663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Production of Polyclonal Antibodies in Laboratory Animals. The Report and Recommendations of ECVAM Workshop 35.
    Leenaars PP; Hendriksen CF; de Leeuw WA; Carat F; Delahaut P; Fischer R; Halder M; Hanly WC; Hartinger J; Hau J; Lindblad EB; Nicklas W; Outschoorn IM; Stewart-Tull DE
    Altern Lab Anim; 1999; 27(1):79-102. PubMed ID: 25423403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ECVAM and the Promotion of International Co-operation in the Development, Validation and Acceptance of Replacement Alternative Test Methods.
    Balls M
    ALTEX; 1999; 16(4):280-282. PubMed ID: 11107329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimisation of the EpiDerm test protocol for the upcoming ECVAM validation study on in vitro skin irritation tests.
    Kandárová H; Liebsch M; Genschow E; Gerner I; Traue D; Slawik B; Spielmann H
    ALTEX; 2004; 21(3):107-14. PubMed ID: 15329774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative Approaches and Tests in Ecotoxicology: A Review of the Present Position and the Prospects for Change, Taking into Account ECVAM's Duties, Topic Selection and Test Criteria.
    Walker CH
    Altern Lab Anim; 1998; 26(5):649-77. PubMed ID: 26042492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the Embryonic Stem Cell Test and application and use in the pharmaceutical industry.
    Paquette JA; Kumpf SW; Streck RD; Thomson JJ; Chapin RE; Stedman DB
    Birth Defects Res B Dev Reprod Toxicol; 2008 Apr; 83(2):104-11. PubMed ID: 18361453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ECVAM's role in the implementation of the Three Rs concept in the field of biologicals.
    Hendriksen C; Cussler K; Halder M
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():41-6. PubMed ID: 12513650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The test chemical selection procedure of the European Centre for the Validation of Alternative Methods for the EU Project ReProTect.
    Pazos P; Pellizzer C; Stummann TC; Hareng L; Bremer S
    Reprod Toxicol; 2010 Aug; 30(1):161-99. PubMed ID: 20399849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.